You are here
Rayaz MalikCorneal confocal microscopy (CCM) in MS; a three minute, non-invasive imaging technique for detecting disease. Axonal loss contributes to neurological...
David BatesProfessor Bates winds up this session by thanking the four speakers who are the 2016 GMSI award recipients, and encourages...
David BatesAfter the presentation of the GMSI Award 2015 winners Professor Bates announced, that the GMSI Award 2016 is open for entries.
Gabriele de LucaDr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.
GMSI Award 2015 – Driving microglia metabolism towards remyelination and restoration of brain damage in multiple sclerosis
Claudia VerderioAccording to Dr. Verderio, the new proposal stemmed from data on the biological activity of vesicles from microglia cells, on the proliferation, differentiation and myelination of oligodendrocyte precursor cells (OPCs).
Laura AirasIn her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
Elga de VriesMicroglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective.
David BatesProfessor Bates briefly summarised progress made by the recipients of the 2013 and 2014 grants.
Steven HildemannMerck-Serono's pipeline focuses on difficult to treat diseases with a high unmet medical need, in the four areas of oncology, immuno-oncology, immunology and multiple sclerosis.
David BatesProfessor Bates said that the GMSI [Grant for Multiple Sclerosis Innovation] was first awarded in 2013. Merck Serono provides research grants of up to 1 million Euros and thereby demonstrated its commitment to immunology...